TOUCH®

CMC 1 PROSTHESIS

Media Kit

Components

KeriMedical
medartis group

Company Introduction

« Fully committed to hand and wrist only"

KeriMedical's mission is to design and provide high-quality orthopedic solutions for the hand and wrist, based on continuous innovation and a commitment to understanding the needs of healthcare professionals, in order to improve patient care.

Founded in 2016 by Bernard Prandi and Dougal Bendjaballah, KeriMedical was born out of the realization that hand surgery—neglected by multinational orthopedic companies—needed to be developed and supported.

Since 2025, Medartis has been the sole shareholder of KeriMedical. This merger marks the beginning of a new chapter of growth and innovation, strengthening our international presence and accelerating the rollout of our solutions, particularly following the FDA approval of our TOUCH® CMC 1 prosthesis.

KeriMedical's goal is to combine its own expertise with that of surgeons to provide safe and effective medical devices worldwide.

Core Values Guiding Our Actions

Our Vision

To establish ourselves as a global leader in hand and wrist surgery by advancing surgical practices through cutting-edge technologies, ongoing research, and close collaboration with medical experts.

Our Ambition

Accelerate the development and global deployment of innovative solutions, while enhancing clinical impact and delivering lasting improvements in patient outcomes.

Our Values

KeriMedical's values are our guiding principles. They shape our growth and strategic decisions. They define our shared goals and guide our choices, while reflecting what is most important to our organization and our partners.

These values form the foundation of our identity and culture. They guide our actions, support our strategy, and foster a harmonious and collaborative environment. They also serve as a framework for establishing our internal policies and our code of ethics, ensuring that all our initiatives remain consistent with our mission and our goals.

The definition of our values is part of a collaborative process, shaped by the employees themselves, ensuring that our values are authentic and truly embodied.

The Foundations of Our Success

Innovation

For us, innovation is the driving force behind our daily work. We actively invest in research to develop and provide innovative and effective solutions that address today's health challenges.

Our goal is clear: to remain committed to the pursuit of excellence in order to improve patient care and bring about lasting change in their healthcare journey.

Quality

For us, quality is non-negotiable: it is at the heart of everything we do. We take great pride in ensuring the reliability and performance of our devices, rigorously adhering to the industry's most stringent standards.

Our goal is to ensure consistent quality, so that we can provide surgeons with the excellence and safety they have come to expect from our expertise.

Service

We are committed to working alongside surgeons to advance the field toward greater precision, better control, and enhanced safety.

This core value guides our daily efforts, as we believe that by working closely with healthcare experts, we can transform modern surgery and provide patients with the highest quality of care.

TOUCH®
CMC 1 PROSTHESIS

Indication
TOUCH® CMC 1 Prosthesis is intended for 1st carpometacarpal (CMC) primary total joint replacement (arthroplasty) in patients with symptomatic Eaton-Littler Stage II or III osteoarthritis (OA).

History of the prosthesis
The Trapeziometacarpal (TMC) prosthesis is the result of a legacy spanning more than 60 years of French innovation, which has led to the development of five generations of prostheses.

1st generation (1970–1990): The emergence of total TMC arthroplasty, with predominantly cemented implants using either Metal-on-Metal or Metal-on-Polyethylene bearing surfaces.

2nd generation (1990–2005): The advent of modern concepts, marking the end of cemented fixation and the gradual abandonment of the Metal-on-Metal concept in favor of alternative solutions aimed at preventing metallosis.

3rd generation (2005–2010): Validation of the «ball-and-socket» design, featuring cementless fixation to restore the joint's natural function, along with significant improvements in the quality of bone anchorage.

4th generation (2010–2020): Introduction of Dual Mobility, a major advancement that dramatically reduced the risk of dislocation while improving overall technical performance.

5th generation (since 2021): Adoption of highly cross-linked polyethylene, reducing wear by a factor of 3.5 and thereby extending the implant's longevity.

TOUCH®
CMC 1 PROSTHESIS

The TOUCH® project represents the culmination of a strategic vision aimed at redefining the treatment of rhizarthrosis through French technological innovation. This large-scale project has been underpinned by investment in R&D and clinical research since 2017.

June 2018 - Obtaining CE marking for the conical cup

September 2019 - Launch and CE certification of our dedicated (ancillary) instruments, designed to optimise surgical procedures.

May 2020 - A major technological milestone with the CE marking of TOUCH® Cross-linked (incorporating highly cross-linked polyethylene).

July 2025 – FDA approval for CMC 1 osteoarthritis treatment
In July 2025, TOUCH® CMC 1 Prosthesis has officially received FDA Premarket Approval (PMA), marking a significant achievement in the treatment of CMC1 osteoarthritis. This approval recognizes our innovative product for meeting the highest standards of safety and efficacy in the U.S. healthcare market.

September 2025 – First TOUCH® CMC 1 prosthesis implanted in the USA.

About TOUCH® CMC 1 Prosthesis

+190,000
Prostheses
implanted worldwide

40
Countries
served worldwide

45
scientific publications
available (CLICK HERE)

Data from 2017 to 2026

Our Other Products

KeriFlex®

SILICONE FINGER JOINT IMPLANTS

Indication

The KeriFlex® PIP-MCP implant replaces joints affected by symptomatic arthritis (rheumatoid, degenerative, or post-traumatic).

History of the KeriFlex®

June 2018 – Launch of the R&D programme
July 2020 - Obtaining CE marking
July 2022 - FDA approval

Contact

Medartis Inc. 1195 Polk Drive Warsaw IN 46582
P: 574-376-2404
E: USA-Touch@medartis.com

FIND US
LinkedIn: KERIMEDICAL SA
Vimeo: https://vimeo.com/kerimedical?fl=pp&fe=sh
YouTube: www.youtube.com/@KeriMedical
Website: www.kerimedical.us

KeriMedical

medartis group

www.kerimedical.us